Novartis completes acquisition of Brandon Capital-backed Myricx Bio - NVS News | RalliesNovartis completes acquisition of Brandon Capital-backed Myricx Bio
N
NVS• Novartis completes Myricx Bio acquisition
- Brandon Capital portfolio company Myricx Bio became an indirect, wholly owned subsidiary of Novartis on Aug. 28, 2026.
- The deal gives Novartis control of Myricx Bio’s N-myristoyltransferase inhibitor payload platform for antibody-drug conjugates.
- Novartis plans to advance NMTi-ADCs across multiple solid tumor settings, targeting improved efficacy with better tolerability.
